TAMPA, Fla., Oct. 1, 2024 /PRNewswire/ -- Wellcare, a company offering a range of Medicare products and the Medicare brand and company of Centene Corporation (NYSE: CNC), will offer Medicare Advantage (MA) products in 32 states, including its newest state, Iowa, during the 2025 Medicare Annual Enrollment Period (AEP), which begins Oct. 15, 2024 and runs through Dec. 7, 2024. Enroll by Dec. 7, 2024, for coverage starting Jan. 1, 2025.
Experience the full interactive Multichannel News Release here: https://www2.multivu.com/centene_corporation/9251052-en-wellcare-medicare-advantage-and-medicare-prescription-drug-plans
"We have worked hard to build a robust product portfolio that offers outstanding plans to support our members' entire well-being," said Wellcare Chief Executive Officer, Michael Carson. "Wellcare remains focused on meeting the needs of the most vulnerable beneficiaries in our footprint through our strong dual-eligible products, and we continue to invest in services across the organization to provide high-quality care and the best experience possible."
Wellcare's 102 Prescription Drug Plans (PDP) will continue to be available nationwide.
"In the face of rising pharmacy costs in Medicare Part D and an uncertain regulatory environment in 2025, Wellcare is pleased to provide a portfolio of PDPs to support seniors in managing their drug costs," said Centene's Senior Vice President of Clinical & Specialty Services, Sarah Baiocchi. "By participating in the Part D Premium Stabilization Demonstration, Wellcare will offer a $0 premium on the Value Script plan in 43 out of 50 states and will be under the benchmark in 49 of 50 states."
The company has invested $22 million into its member online Find a Provider tool, campaign platforms, member website and portal accounts, creating an enhanced set of digital tools and resources for members and prospective members. Key member onboarding videos are also now available in eight languages: Spanish, Vietnamese, Russian, Tagalog, Chinese Traditional, Chinese Taiwan, Chinese Hong Kong and Korean.
This summer, Wellcare announced it will discontinue offering MA products in Alabama, Massachusetts, New Hampshire, New Mexico, Rhode Island and Vermont in 2025. Wellcare will continue to offer PDP in these states, and this decision does not impact the company's Marketplace or Medicaid contracts in these markets. Wellcare will continue serving MA members in these six states through the end of 2024.
The 2025 Medicare AEP begins on Oct. 15, 2024, and continues through Dec. 7, 2024. Most plans selected during AEP are effective Jan. 1, 2025. For more details about Centene's MA plans and Medicare PDPs, visit www.WellcareNow.com.
Wellcare's 2025 Plan Offerings
For 2025, Wellcare will offer plans to more than 51 million beneficiaries, which accounts for 77% of the eligible beneficiaries in 32 states and more than 1,800 counties. Wellcare also added 126 counties to its footprint across the following states: California, Illinois, Iowa, Mississippi, New York, Texas and Washington.
MAPD Highlights:
In 2025, a variety of plan offerings for value-conscious beneficiaries are available with predictable copays and extra benefits:
Benefits and allowance amounts vary by plan. Please call for more details. Allowance amounts cannot be combined with other benefit allowances which may be on the prepaid card. Limitations and restrictions may apply.
Medicare PDP Highlights:
About Wellcare
For more than 20 years, Wellcare has offered a range of Medicare products, including Medicare Advantage and Medicare Prescription Drug Plans (PDP), which offer affordable coverage beyond Original Medicare. Wellcare is the Medicare brand of Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives. Beginning Jan. 1, 2022, Centene's Medicare brands, including Allwell, Health Net, Fidelis Care, Trillium Advantage, 'Ohana Health Plan and TexanPlus transitioned to the Wellcare brand. For more information about Wellcare, visit www.wellcare.com.
'Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. Wellcare is the Medicare brand for Centene Corporation, an HMO, PPO, PFFS, PDP plan with a Medicare contract and is an approved Part D Sponsor. Our D-SNP plans have a contract with the state Medicaid program. Enrollment in our plans depends on contract renewal. Our plans use a formulary. Washington residents: "Wellcare" is issued by Coordinated Care of Washington, Inc., a subsidiary of Centene Corporation. Health Net Life Insurance Company is contracted with Medicare for PPO plans. "Wellcare by Health Net" is issued by Health Net Life Insurance Company. "Wellcare" is issued by WellCare Health Insurance of Washington, Inc., a subsidiary of Centene Corporation. "Wellcare" is issued by WellCare Prescription Insurance, Inc. For accommodations of persons with special needs at meetings, call [1-877-MY-WELLCARE] TTY (711). There is no obligation to enroll. Wellcare's pharmacy network includes limited lower-cost, preferred pharmacies in rural areas of Nebraska. The lower costs advertised in our plan materials for these pharmacies may not be available at the pharmacy you use. For up-to-date information about our network pharmacies, including whether there are any lower-cost preferred pharmacies in your area, please call 1-800-977-7522 (TTY: 711) for Wellcare Assist Open (PPO), Wellcare Giveback (HMO-POS), and Wellcare Simple Open (PPO) in NE or consult the online pharmacy directory at www.wellcare.com/NE. For Louisiana D-SNP members: As a Wellcare HMO D-SNP member, you have coverage from both Medicare and Medicaid. You receive your Medicare health care and prescription drug coverage through Wellcare and are also eligible to receive additional healthcare services and coverage through Louisiana Medicaid. Learn more about providers who participate in Louisiana Medicaid by visiting www.myplan.healthy.la.gov/en/find-provider or https://www.louisianahealthconnect.com. For detailed information about Louisiana Medicaid benefits, please visit the Medicaid website at https://ldh.la.gov/medicaid and select the "Learn about Medicaid Services" link. To request a written copy of our Medicaid Provider Directory, please contact us. Louisiana D-SNP prospective enrollees: For detailed information about Louisiana Medicaid benefits, please visit the Medicaid website at https://ldh.la.gov/medicaid or https://www.louisianahealthconnect.com. To request a written copy of our Medicaid Provider Directory, please contact us. Notice: TennCare is not responsible for payment for these benefits, except for appropriate cost sharing amounts. TennCare is not responsible for guaranteeing the availability or quality of these benefits. Any benefits above and beyond traditional Medicare benefits are applicable to Wellcare Medicare Advantage only and do not indicate increased Medicaid benefits. Texas D-SNP prospective enrollees: For detailed information about Texas Medicaid benefits, please visit the Texas Medicaid website at https://www.hhs.texas.gov/services/health/medicaid-chip/medicaid-chip-members/starplus. To request a written copy of our Medicaid Provider Directory, please contact us. New Mexico (NM) Dual Eligible Special Needs Plan (D-SNP) Members: As a Wellcare by Allwell D-SNP member, you have coverage from both Medicare and Medicaid. Medicaid services are funded in part by the state of New Mexico. NM Medicaid benefits may be limited to payment of Medicare premiums for some members. Louisiana D-SNP prospective enrollees: For detailed information about Louisiana Medicaid benefits, please visit the Medicaid website at https://ldh.la.gov/medicaid or https://www.louisianahealthconnect.com. To request a written copy of our Medicaid Provider Directory, please contact us. Wellcare by Allwell (HMO and HMO SNP) includes products that are underwritten by Superior HealthPlan, Inc. Wellcare (HMO and HMO SNP) includes products that are underwritten by WellCare of Texas, Inc., WellCare National Health Insurance Company, and SelectCare of Texas, Inc. Please contact your plan for details. Other Pharmacies/Physicians/Providers are available in our network.
Last Trade: | US$60.37 |
Daily Change: | 0.02 0.03 |
Daily Volume: | 3,998,309 |
Market Cap: | US$30.480B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB